Psychedelic Drug Outperforms Nicotine Patches in Smoking Cessation

Research from Johns Hopkins University suggests that psilocybin, a compound found in “magic mushrooms,” may significantly enhance smoking cessation efforts when combined with cognitive behavioral therapy (CBT). Published in March 2024, this study indicates that a single dose of psilocybin could be more effective than traditional nicotine patches, a finding that could reshape approaches to treating nicotine addiction.

The urgency of this research is underscored by the fact that over 16 million Americans live with smoking-related illnesses, and approximately 480,000 deaths annually in the United States are linked to smoking. Despite the availability of various cessation aids, including nicotine patches and prescription medications, less than 10% of smokers manage to quit each year, according to data from the Centers for Disease Control and Prevention (CDC).

In this study, researchers divided 82 adult smokers who had previously attempted to quit into two groups. One group utilized a nicotine patch for a duration of eight to ten weeks, delivering a consistent dose of nicotine to mitigate withdrawal symptoms. The other group was administered a single high dose of psilocybin in a controlled therapeutic setting, guided by trained facilitators. Both groups participated in a 13-week CBT program designed to help identify triggers and modify addictive behaviors.

At the six-month follow-up, results revealed a stark contrast between the groups. Among the participants, 17 individuals from the psilocybin group were smoke-free, compared to just four in the nicotine patch group. The psilocybin group exhibited over six times the odds of quitting smoking. Furthermore, participants in this group reported smoking approximately 50% fewer cigarettes daily between the target quit date and the follow-up.

This is not the first instance of psilocybin demonstrating potential in smoking cessation. A smaller pilot study involving 15 participants had previously shown that multiple sessions of psilocybin combined with CBT resulted in around 80% abstinence at six months, with about 60% of participants remaining smoke-free a year or more after treatment.

The implications of these findings are significant, as they suggest that psilocybin therapy may activate different mechanisms in the brain compared to conventional addiction treatments. Researchers noted that psilocybin does not interact directly with nicotine receptors but instead helps users reframe their thought processes, making it easier to abandon detrimental habits. The study authors highlighted this unique aspect of psilocybin therapy, stating, “Psilocybin’s lack of direct interaction with nicotinic acetylcholine receptors highlights psychedelic therapy as a unique approach.”

Experts outside the study have expressed enthusiasm regarding these findings. Megan Piper, director of the University of Wisconsin Center for Tobacco Research and Intervention, emphasized the need for innovative treatments, stating on NPR’s “All Things Considered,” “It’s been 20 years since we’ve had a new medication to help people quit smoking. We need something novel, and this is definitely a novel approach.”

Despite the promising results, the study does have limitations. The absence of a placebo group means participants were aware of their treatment, which could have influenced their expectations and perceptions. Additionally, the sample was predominantly comprised of highly educated individuals, lacking racial and ethnic diversity, and many had previous psychedelic experience, factors that may have impacted the outcomes.

Looking ahead, the research team plans to conduct a larger-scale study to further explore the efficacy of psilocybin as a smoking cessation tool. They aim to refine treatment protocols, assess cost-effectiveness, and determine the feasibility of broader implementation. These efforts may pave the way for a new frontier in addiction treatment, ultimately contributing to the fight against one of the leading causes of preventable death.